Tandem Wins FDA Clearance On First Stand-Alone Glycemic Controller
Executive Summary
Tandem Diabetes Care received FDA clearance for its Control-IQ technology for use with Tandem's t:slim X2 insulin pump and Dexcom's G6 continuous glucose monitoring system, making it the first hybrid closed-loop system to deliver automatic correction boluses and adjust background insulin levels to help prevent high and low blood sugars.
You may also be interested in...
Bigfoot Biomedical Secures $57M In New Funding To Support Commercialization Of Diabetes Management System
As Bigfoot awaits FDA clearance for its Bigfoot Unity System, the diabetes treatment company’s business model calls for packing the System as part of a one-stop-shop monthly subscription model.
ADA 2020: Tandem Wins FDA Nod For T:Slim Pump Technology In Children; Positive Feedback on Studies
After announcing positive results at the American Diabetes Association conference and an expanded FDA approval for its insulin pump delivery system, Tandem Diabetes Care’s CEO outlines its path forward.
ADA 2020: US Pivotal Trial Data Support Medtronic’s Next-Gen Insulin Pump
Clinical data presented during the virtual ADA meeting show Medtronic’s MinMed 780G hybrid closed-loop insulin system, an upgraded version of the company's 770G system, improved patients’ ability to keep their blood-glucose levels within target range.